Combined treatment modality for anaplastic oligodendroglioma: A phase II study

Journal of Neuro-Oncology

Volumn 43, Issue 2, 1999, Pages 179-185

  Jeremic, Branislav ^a,d   Shibamoto, Yuta ^c   Grujicic, Danica ^b   Milicic, Biljana ^a   Stojanovic, Miroslav ^a   Nikolic, Nebojsa ^a   Dagovic, Aleksandar ^a   Aleksandrovic, Jasna ^a  

^a University Hospital   (Serbia)

^b Clinical Center   (Serbia)

^c KYOTO UNIVERSITY   (Japan)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Anaplastic oligodendroglioma; Chemotherapy; Radiotherapy; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; LOMUSTINE; PROCARBAZINE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADULT; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FATIGUE; FEMALE; HISTOLOGY; HUMAN; INFECTION; LETHARGY; LEUKOPENIA; MALE; NAUSEA; OLIGODENDROGLIOMA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PROGNOSIS; SEIZURE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0032877838     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006206800947     Document Type: Article

References (41)

1. Chin HW, Hazel JJ, Kim TH, Webster J: Oligodendrogliomas: A clinical study of cerebral oligodendrogliomas. Cancer 45: 1458-1466, 1980
2. Mork SJ, Lindegaard KKF, Halvorsen TB, Lehmann EH, Solgaard T, Hatlevoll R, Harvei S, Ganz J: Oligodendroglioma: Incidence and biological behavior in a defined population. J Neurosurg 63: 881-889, 1985
3. Kernohan JW, Sayre GP: Tumors of the central nervous system. In: Atlas of Tumor Pathology, Fasc. 35. Armed Forces Institute of Pathology, Washington DC, 1952
4. Smith MT, Ludwig CL, Godfrey AD, Armbrustmacher VW: Grading of oligodendrogliomas. Cancer 52: 2107-2114, 1983
5. Zulch KJ: Histological typing of tumors of the central nervous system. World Health Organization (Intern Classification of Tumors), No. 21, 1979
6. Bullard DE, Rawlings CE, Phillips B, Cox EB, Schold SC, Burger P, Halperin EC: Oligodendroglioma: An analysis of the value of radiation therapy. Cancer 60: 2179-2188, 1987
7. Lindegaard K, Mork SJ, Eide GE, Halvorsen TB, Hatlevoll R, Solgaard T, Dahl O, Ganz J: Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma. J Neurosurg 67: 224-230, 1987
8. Reedy DP, Bay JW, Hahn JF: Role of radiation therapy in the treatment of cerebral oligodendroglioma: An analysis of 57 cases and a literature review. Neurosurgery 13: 499-503, 1983
9. Wallner KE, Gonzales M, Sheline GE: Treatment of oligodendrogliomas with or without post operative irradiation. J Neurosurg 68: 684-688, 1988
10. Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme I, Nesbakken R, Hatlevoll R, Lindgren M, Brun A, Lindgren S, Notter G, Anderson AP, Elgen K: Combined modality therapy of operated astrocytomas Grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time : A prospective multicenter trial of the Scandinavian Glioblastoma Study group. Cancer 47: 649-652, 1981
11. Walker MD, Alexander E, Hunt WE, MacCarty CS, Mahaley MS, Mealey MS, Jr, Mealey MS, Sr, Norrell HA, Owens G, Ranshoff JR, Wilson CB, Gehan EA, Strike TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49: 333-343, 1978
12. Walker MD, Green SB, Byar DP, Alexander E, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Owens G, Ranshoff J, Robertson JT, Shapiro WR, Smith KR, Wilson CB, Strike TA: Randomized comparison of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323-1329, 1980
13. Chang CH, Horton J, Schoenfeld D, Salazar O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y: Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multi-disciplinary management of malignant gliomas. Cancer 52: 997-1007, 1983
14. Green SB, Byar DP, Walker MD: Comparison of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67: 121-132, 1983
15. Eyre HJ, Quagliana JM, Eltringham JR: Randomized comparisons of radiotherapy and CCNU vs. radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. A Southwest Oncology Group report. J Neuro-Oncol 1: 171-177, 1983
16. Levin VA, Edwards MS, Wright DC: Modified procarbazine, CCNU, and vincristine (PCV-3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64: 237-241, 1980
17. Jeremic B, Jovanovic D, Djuric Lj, Jevremovic S, Mijatovic Lj: Advantage of post-radiotherapy chemotherapy with CCNU, Procarbazine and vincristine (mPCV) over chemotherapy with VM-26 and CCNU. J Chemother 4: 123-126, 1992
18. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, Wilson CB: Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic astrocytoma: NCOG 6G91 final report. Int J Radiat Oncol Biol Phys 18: 321-324, 1990
19. Hart MN, Petito CK, Earle KM: Mixed gliomas. Cancer 33: 134-140, 1974
20. International Commission on Radiological Units and Measurements. Dose specification for reporting external beam therapy with photons and electrons. ICRU Report No. 29: 3-13, 1978
21. Jeremic B, Grujicic D, Jevremovic S, Stanisavljevic B, Milojevic Lj, Mijatovic Lj: Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma. A phase II study. J Clin Oncol 10: 1074-1077, 1992
22. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
23. Cox JD, Stetz JA, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for the Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31: 1341-1346, 1995
24. Kyritisis AP, Yung WKA, Bruner J: The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 32: 365-371, 1993
25. Allison RR, Schulsinger A, Vongtama V, Barry T, Shin KH: Radiation and chemotherapy improve outcome in oligodendroglioma. Int J Radiat Oncol Biol Phys 37: 399-403, 1997
26. Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23: 360-364, 1988
27. Cairncross JG, Macdonald DR: Chemotherapy for oligodendroglioma: Progress report. Arch Neurol 48: 225-227, 1991
28. Cairncross JG, Macdonald DR, Ramsay DA: Aggressive oligodendroglioma. A chemosensitive tumor. Neurosurgery 31: 78-82, 1992.
29. Macdonald DR, Gaspar LE, Cairncross JG: Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27: 573-574, 1990
30. Macdonald DR, O'Brien RA, Gilbert JJ, Cairncross JG: Metastatic anaplastic oligodendroglioma. Neurology 39: 1593-1596, 1989
31. Cairncross JG, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C, Jr, Wainman N, Eisenhauer E: Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12: 2013-2021, 1994
32. Glass JG, Hochberg FH, Gruber ML: The treatment of oligodendrogliomas and mixed oligodendrogliomas-astrocytomas with PCV chemotherapy. J Neurosurg 76: 741-745, 1992
33. Brown M, Cairncross JG, Vick NA: Differential response of recurrent oligodendroglioma versus astrocytoma to intravenous melphalan (Abstract). Neurology 40 (Suppl 1): 397-398, 1990
34. Schold SC, Cairncross JG, Bullard DE: Chemotherapy of primary brain tumors. In: Wilkins RH, Rengachary SS (eds) Neurosurgery. McGraw-Hill, New York, 1985, pp 1143-1153
35. Winger MJ, Macdonald DR, Cairncross JG: Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg 71: 487-493, 1989
36. Shaw EG, Scheithauer B, O'Fallon J: Astrocytomas (A), oligo-astrocytomas (OA), and oligodendrogliomas (O): A comparative survival study (Abstract). Neurology 42 (Suppl 3): 342, 1992
37. Jeremic B, Grujicic D, Antunovic V, Djuric Lj, Stojanovic M, Shibamoto Y: Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: A phase II study. Int J Radiat Oncol Biol Phys 30: 1179-1185, 1994
38. Jeremic B, Grujicic D, Antunovic V, Djuric Lj, Shibamoto Y: Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study. Am J Clin Oncol (CCT) 18: 449-453, 1995
39. Bishop M, de la Monte SM: Dual lineage of astrocytomas. Am J Pathol 135: 517-527, 1989
40. de la Monte SM: Uniform lineage of oligodendrogliomas. Am J Pathol 135: 529-540, 1989
41. Jeremic B, Grujicic D, Antunovic V, Stojanovic M, Shibamoto Y: Influence of the extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach. J Neuro-Oncol 21: 177-185, 1994